ORIGINAL ARTICLE: Are Anti-Beta2-Glycoprotein-I Antibodies Markers for Recurrent Pregnancy Loss in Lupus Anticoagulant/Anticardiolipin Seronegative Women?

Authors

  • Jaume Alijotas-Reig,

    1. Systemic Autoimmune Disease Unit, Department of Internal Medicine I, Hospital Universitari Vall d’Hebron, Barcelona, Spain
    2. Department of Medicine, Universitat Autonoma, Barcelona, Spain
    3. Institut Universitari Dexeus Universitat Autonoma, Barcelona, Spain
    Search for more papers by this author
  • Manel Casellas-Caro,

    1. Department of Obstetrics, Hospital Universitari Vall d’Hebron, Universitat Autonoma, Barcelona, Spain
    Search for more papers by this author
  • Raquel Ferrer-Oliveras,

    1. Department of Obstetrics, Hospital Universitari Vall d’Hebron, Universitat Autonoma, Barcelona, Spain
    Search for more papers by this author
  • Elisa Llurba-Olive,

    1. Department of Obstetrics, Hospital Universitari Vall d’Hebron, Universitat Autonoma, Barcelona, Spain
    Search for more papers by this author
  • Eduard Hermosilla,

    1. Department of Preventive Medicine, Epidemiology and Statistics, Hospital Universitari Vall d’Hebron, Universitat Autonoma, Barcelona, Spain
    Search for more papers by this author
  • Miquel Vilardell-Tarres,

    1. Systemic Autoimmune Disease Unit, Department of Internal Medicine I, Hospital Universitari Vall d’Hebron, Barcelona, Spain
    2. Department of Medicine, Universitat Autonoma, Barcelona, Spain
    Search for more papers by this author
  • Lluis Cabero-Roura

    1. Department of Obstetrics, Hospital Universitari Vall d’Hebron, Universitat Autonoma, Barcelona, Spain
    Search for more papers by this author

Jaume Alijotas-Reig, Josep Mª de Segarra, 2-F, 08190-Sant Cugat del Vallés, Barcelona, Spain.
E-mail: 16297jar@comb.es, jalijotas@vhebron.net

Abstract

Problem  Anti-beta2-Glicoprotein-1 antibodies (anti-β2GPI-ab) have been related to recurrent miscarriage (RM) with conflicting results. The aim was to evaluate the role of anti-β2-GPI-ab as unique biological marker in RM related to antiphospholipid (aPL).

Method of study  A cohort study that included 59 cases, divided in two groups, was designed: group 1 comprised 43 pregnant women with ‘obstetric’ antiphospholipid syndrome (APS) and group 2 included 16 cases with similar complaints but only having repeatedly anti-β2-GPI-ab. Previous thrombosis and/or inherited thrombophilia were excluded. Lupus anticoagulant, anticardiolipin antibodies (aCA), anti-β2-GPI-ab, and other autoantibodies were analyzed. Miscarriages, premature births, pre-eclampsia, live births, placental and systemic thromboses were studied.

Results  No differences in previous obstetric complications were detected (= 1.00–0.164). After the treatment, differences in number of obstetric complications were not seen (= 1.00). Live births were similar in two groups (88.4% and 93.7%; = 1.00). Placental thrombosis was equal in both groups, 93.3% versus 80% (= 1.00).

Conclusion  These results suggest that anti-β2-GPI-ab may be considered a biological marker for obstetric APS.

Ancillary